{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:59:21Z","timestamp":1759730361494},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T00:00:00Z","timestamp":1624060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gefapixant (MK\u20107264, AF\u2010219) is a first\u2010in\u2010class P2X3 antagonist in development for refractory or unexplained chronic cough. Gefapixant is primarily cleared by renal excretion. To assess the importance of the multidrug and toxin extrusion protein 1 (MATE1) and MATE2K transporters in the elimination of gefapixant, a drug\u2010drug interaction study was conducted evaluating the effect of coadministration of a single dose of pyrimethamine, a competitive inhibitor of MATE1 and MATE2K, on the single\u2010dose pharmacokinetics of gefapixant in healthy participants. Safety and tolerability were also assessed. In this open\u2010label, 2\u2010period, fixed\u2010sequence study, a 45\u2010mg dose of gefapixant was administered to 12 participants in period 1. After a 7\u2010day washout, a 50\u2010mg dose of pyrimethamine was administered 3\u00a0hours before a 45\u2010mg dose of gefapixant in period 2. Compared with the administration of gefapixant alone, concomitant dosing of gefapixant with pyrimethamine increased the total gefapixant plasma exposure (area under the plasma concentration\u2013time curve from time 0 to infinity) by 24%, reduced gefapixant renal clearance by 30%, and increased gefapixant mean terminal half\u2010life from 7.7 to 10.3\u00a0hours. The most frequently reported adverse events were dysgeusia, hypogeusia, and dry mouth; all adverse events were considered of mild intensity and resolved by the end of the study. These results support that MATE1 and\/or MATE2K contribute to the renal clearance of gefapixant, but the effect of inhibition of these transporters on gefapixant pharmacokinetics is not considered clinically meaningful.<\/jats:p>","DOI":"10.1002\/cpdd.988","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T11:49:43Z","timestamp":1624103383000},"page":"123-128","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1\/2K, on the Pharmacokinetics of Gefapixant (MK\u20107264), a P2X3 Receptor Antagonist"],"prefix":"10.1002","volume":"11","author":[{"given":"Jesse C.","family":"Nussbaum","sequence":"first","affiliation":[{"name":"MRL, Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azher","family":"Hussain","sequence":"additional","affiliation":[{"name":"MRL, Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bennett","family":"Ma","sequence":"additional","affiliation":[{"name":"MRL, Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Chris","family":"Min","sequence":"additional","affiliation":[{"name":"MRL, Merck &amp; Co., Inc.  Kenilworth New Jersey USA"},{"name":"Enterin, Inc  Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Evers","sequence":"additional","affiliation":[{"name":"MRL, Merck &amp; Co., Inc.  Kenilworth New Jersey USA"},{"name":"Johnson &amp; Johnson, Janssen Pharmaceuticals  Springhouse Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[{"name":"MRL, Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graigory","family":"Garrett","sequence":"additional","affiliation":[{"name":"MRL, Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[{"name":"MRL, Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"MRL, Merck &amp; Co., Inc.  Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,19]]},"reference":[{"issue":"159","key":"e_1_2_11_2_1","first-page":"1","article-title":"Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001\u201302","volume":"13","author":"Schappert SM","year":"2006","journal-title":"Vital Health Stat"},{"issue":"27","key":"e_1_2_11_3_1","first-page":"1","article-title":"National Ambulatory Medical Care Survey: 2007 summary","author":"Hsiao CJ","year":"2010","journal-title":"Natl Health Stat Rep"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00218714"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70043-2"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.5.1710"},{"key":"e_1_2_11_7_1","volume-title":"AHRQ Comparative Effectiveness Reviews","author":"McCrory DC","year":"2013"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005116"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-79842-2_2"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-020-00377-8"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2012.233460"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-011-9271-6"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.90360.2008"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61255-1"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01615-2019"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30471-0"},{"issue":"1","key":"e_1_2_11_17_1","first-page":"887.5","article-title":"Pharmadynamic (PD) & pharmacokinetic (PK) properties of AF\u2010219: first in class, selective, clinical P2X3 antagonist in development for chronic pain and related conditions","volume":"27","author":"Ford AP","year":"2013","journal-title":"FASEB J"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.163642"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1216"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.36"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12577"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.988","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.988","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:39:41Z","timestamp":1693229981000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,19]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/cpdd.988"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.988","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,19]]},"assertion":[{"value":"2021-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}